Ocular Therapeut (OCUL)

$8.80 +0.45 (5.39%)
Market Cap 1.82B
Revenue (ttm) 51.95M
Net Income (ttm) -265.94M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -511.92%
Debt to Equity Ratio 0.12
Volume 1,824,200
Avg Vol 3,173,694
Day's Range N/A - N/A
Shares Out 218.96M
Stochastic %K 82%
Beta 0.89
Analysts Strong Sell
Price Target $26.10

Company Profile

Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing AXPAXLI, an axitinib intravitreal hydrogel that i...

Industry: Biotechnology
Sector: Healthcare
Phone: 781 357 4000
Address:
15 Crosby Drive, Bedford, United States
onlyGreenPlz
onlyGreenPlz Jun. 4 at 11:57 PM
$OCUL I heard he left in the blink of an eye.
1 · Reply
MaxKlim
MaxKlim Jun. 4 at 11:18 PM
$OCUL The former head of ophthalmology of the FDA will discuss safety and the future !!! His receivers will make a decision, as he retired and left his pupils!
0 · Reply
QuietTrader
QuietTrader Jun. 4 at 3:34 PM
$OCUL Where are those people doubting this move. In at 8.24 a few days ago, out at 8.90 today with a very nice gain. I hope this goes to the moon to screw all the nasty shorts. I really do. Good luck folks… until we meet again!
0 · Reply
Unicorn2020
Unicorn2020 Jun. 4 at 1:51 PM
$OCUL Don't ever forget French pharmaceutical giant Sanofi made a discreet, formal proposal to acquire Ocular Therapeutix for $16 per share = $2.3 billion valuation. And got rejected!
3 · Reply
Fairvalue10
Fairvalue10 Jun. 4 at 1:50 PM
$OCUL It would be very logical that, as we get closer to June 17, we see a bullish momentum and break above 10. It's quite inconceivable that there are 22 million shorts approaching an event that could be a real catalyst. Tomorrow and next week should be favorable to all longs.
2 · Reply
MaxKlim
MaxKlim Jun. 4 at 1:39 PM
$OCUL back to 9,3$ this week !!!! Go go go
0 · Reply
MaxKlim
MaxKlim Jun. 4 at 12:58 PM
$OCUL
0 · Reply
Fairvalue10
Fairvalue10 Jun. 4 at 12:41 PM
$OCUL Busy, Busy : BEDFORD, Mass., June 04, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced participation at Clinical Trials at the Summit 2026, taking place on June 12-13, 2026, in Las Vegas, Nevada.
0 · Reply
Nikkosi
Nikkosi Jun. 4 at 11:44 AM
$OCUL “Bringing Novel Treatments to Market” on Saturday, June 13th. Alarm is set. I’ll definitely be tuning in and listening attentively—should be an interesting discussion with plenty of valuable insights.
1 · Reply
BuyoutBobby
BuyoutBobby Jun. 4 at 11:12 AM
$OCUL the pipeline of Re-Vana is probably interesting for ophthalmology interested people especially because they are working on sustained release drugs with some big pharma companies.
0 · Reply
Latest News on OCUL
Ocular Therapeutix™ to Participate in Clinical Trials at the Summit 2026

Jun 4, 2026, 7:00 AM EDT - 14 hours ago

Ocular Therapeutix™ to Participate in Clinical Trials at the Summit 2026

Ocular Therapeutix™ to Host Investor Day on June 17, 2026

Jun 2, 2026, 7:00 AM EDT - 2 days ago

Ocular Therapeutix™ to Host Investor Day on June 17, 2026

Ocular Therapeutix Transcript: Stifel 2026 Virtual Ophthalmology Forum

May 26, 2026, 2:30 PM EDT - 9 days ago

Ocular Therapeutix Transcript: Stifel 2026 Virtual Ophthalmology Forum

Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 15, 2026, 7:00 AM EDT - 20 days ago

Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Ocular Therapeutix Transcript: Bank of America Global Healthcare Conference 2026

May 12, 2026, 6:40 PM EDT - 23 days ago

Ocular Therapeutix Transcript: Bank of America Global Healthcare Conference 2026

Ocular Therapeutix Earnings Call Transcript: Q1 2026

May 5, 2026, 8:00 AM EDT - 4 weeks ago

Ocular Therapeutix Earnings Call Transcript: Q1 2026

Ocular Therapeutix Earnings release: Q1 2026

May 5, 2026, 8:00 AM EDT - 4 weeks ago

Ocular Therapeutix Earnings release: Q1 2026

Ocular Therapeutix Quarterly report: Q1 2026

May 5, 2026, 8:00 AM EDT - 4 weeks ago

Ocular Therapeutix Quarterly report: Q1 2026

Ocular Therapeutix reports Q1 EPS (40c), consensus (31c)

2026-05-05T11:59:32.000Z - 4 weeks ago

Ocular Therapeutix reports Q1 EPS (40c), consensus (31c)

Ocular Therapeutix™ Reports First Quarter 2026 Financial Results and Business Highlights

May 5, 2026, 7:00 AM EDT - 4 weeks ago

Ocular Therapeutix™ Reports First Quarter 2026 Financial Results and Business Highlights

Ocular Therapeutix Proxy statement: Proxy filing

Apr 30, 2026, 8:00 AM EDT - 5 weeks ago

Ocular Therapeutix Proxy statement: Proxy filing

Ocular Therapeutix Proxy statement: Proxy filing

Apr 30, 2026, 8:00 AM EDT - 5 weeks ago

Ocular Therapeutix Proxy statement: Proxy filing

Ocular Therapeutix enrolls first patient in Axpali trial

2026-04-29T13:00:19.000Z - 5 weeks ago

Ocular Therapeutix enrolls first patient in Axpali trial

Ocular Therapeutix™ Announces First Patient Enrolled in SOL-X Long-Term Extension Trial for AXPAXLI™ in Wet AMD

Apr 29, 2026, 7:00 AM EDT - 5 weeks ago

Ocular Therapeutix™ Announces First Patient Enrolled in SOL-X Long-Term Extension Trial for AXPAXLI™ in Wet AMD

Ocular Therapeutix™ to Report First Quarter 2026 Financial Results on May 5, 2026

Apr 28, 2026, 7:00 AM EDT - 5 weeks ago

Ocular Therapeutix™ to Report First Quarter 2026 Financial Results on May 5, 2026

Ocular Therapeutix Transcript: HCW @ Home

Apr 27, 2026, 2:30 PM EDT - 5 weeks ago

Ocular Therapeutix Transcript: HCW @ Home

Ocular Therapeutix reports additional Axpaxli trial data

2026-04-13T11:22:45.000Z - 7 weeks ago

Ocular Therapeutix reports additional Axpaxli trial data

Ocular Therapeutix™ Announces Additional Positive Week 52 Data from Landmark SOL-1 Phase 3 Trial of AXPAXLI™ in Wet AMD

Apr 13, 2026, 7:00 AM EDT - 7 weeks ago

Ocular Therapeutix™ Announces Additional Positive Week 52 Data from Landmark SOL-1 Phase 3 Trial of AXPAXLI™ in Wet AMD

Ocular Therapeutix™ to Present Additional SOL-1 Data and Analyses at Upcoming Scientific Conferences in April

Apr 1, 2026, 7:00 AM EDT - 2 months ago

Ocular Therapeutix™ to Present Additional SOL-1 Data and Analyses at Upcoming Scientific Conferences in April

Ocular Therapeutix Transcript: RBC Capital Markets Virtual Ophthalmology Conference

Mar 25, 2026, 9:30 AM EDT - 2 months ago

Ocular Therapeutix Transcript: RBC Capital Markets Virtual Ophthalmology Conference

EyePoint sues rival Ocular Therapeutix, alleging false claims about eye drug

Mar 20, 2026, 5:24 PM EDT - 2 months ago

EyePoint sues rival Ocular Therapeutix, alleging false claims about eye drug

EYPT

Ocular Therapeutix Transcript: The Citizens Life Sciences Conference 2026

Mar 11, 2026, 9:00 AM EDT - 3 months ago

Ocular Therapeutix Transcript: The Citizens Life Sciences Conference 2026

Ocular Therapeutix price target raised to $27 from $24 at BofA

2026-03-03T11:45:13.000Z - 3 months ago

Ocular Therapeutix price target raised to $27 from $24 at BofA

Ocular Therapeutix price target raised to $28 from $21 at Clear Street

2026-03-02T21:05:53.000Z - 3 months ago

Ocular Therapeutix price target raised to $28 from $21 at Clear Street

Ocular Therapeutix Transcript: TD Cowen 46th Annual Health Care Conference

Mar 2, 2026, 9:10 AM EST - 3 months ago

Ocular Therapeutix Transcript: TD Cowen 46th Annual Health Care Conference

Ocular Therapeutix Transcript: Study update

Mar 2, 2026, 7:30 AM EST - 3 months ago

Ocular Therapeutix Transcript: Study update

Ocular Therapeutix Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

Feb 19, 2026, 10:41 AM EST - 3 months ago

Ocular Therapeutix Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

Ocular Therapeutix selloff brings attractive entry point, says Citizens

2026-02-17T19:15:34.000Z - 3 months ago

Ocular Therapeutix selloff brings attractive entry point, says Citizens

Jefferies stays constructive on Ocular Therapeutix despite SOL-1 selloff

2026-02-17T15:55:17.000Z - 3 months ago

Jefferies stays constructive on Ocular Therapeutix despite SOL-1 selloff

Ocular Therapeutix Transcript: Study result

Feb 17, 2026, 8:00 AM EST - 3 months ago

Ocular Therapeutix Transcript: Study result

Ocular Therapeutix Press release: Study result

Feb 17, 2026, 8:00 AM EST - 3 months ago

Ocular Therapeutix Press release: Study result

Ocular Therapeutix announces SOL-1 Phase 3 of Axpaxli met primary endpoint

2026-02-17T12:17:53.000Z - 3 months ago

Ocular Therapeutix announces SOL-1 Phase 3 of Axpaxli met primary endpoint

Ocular Therapeutix's eye drug superior to Regeneron's Eylea in late-stage trial

Feb 17, 2026, 7:08 AM EST - 3 months ago

Ocular Therapeutix's eye drug superior to Regeneron's Eylea in late-stage trial

REGN

Ocular Therapeutix™ to Announce Topline Data for SOL-1 Phase 3 Superiority Trial in Wet AMD on Tuesday, February 17, 2026

Feb 13, 2026, 5:00 PM EST - 3 months ago

Ocular Therapeutix™ to Announce Topline Data for SOL-1 Phase 3 Superiority Trial in Wet AMD on Tuesday, February 17, 2026

Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Feb 6, 2026, 4:01 PM EST - 4 months ago

Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Ocular Therapeutix reports Q4 EPS (29c), consensus (34c)

2026-02-05T12:05:13.000Z - 4 months ago

Ocular Therapeutix reports Q4 EPS (29c), consensus (34c)

Ocular Therapeutix Annual report: Q4 2025

Feb 5, 2026, 7:00 AM EST - 4 months ago

Ocular Therapeutix Annual report: Q4 2025

Ocular Therapeutix Earnings release: Q4 2025

Feb 5, 2026, 7:00 AM EST - 4 months ago

Ocular Therapeutix Earnings release: Q4 2025

Ocular Therapeutix appoints Robinson as Global Chief Commercial Officer

2026-01-21T12:05:23.000Z - 4 months ago

Ocular Therapeutix appoints Robinson as Global Chief Commercial Officer

MRK

Sanofi prepping higher bid for Ocular Therapeutix, IBD reports

2026-01-15T16:06:19.000Z - 5 months ago

Sanofi prepping higher bid for Ocular Therapeutix, IBD reports

SNY

Ocular Therapeutix rises 11.7%

2026-01-15T15:06:31.000Z - 5 months ago

Ocular Therapeutix rises 11.7%

Ocular Therapeutix price target raised to $21 from $18 at BofA

2025-12-12T13:36:48.000Z - 6 months ago

Ocular Therapeutix price target raised to $21 from $18 at BofA

Mizuho remains bullish on EyePoint as competitor makes move for ‘Pole Position’

2025-12-09T16:15:28.000Z - 6 months ago

Mizuho remains bullish on EyePoint as competitor makes move for ‘Pole Position’

EYPT

Ocular Therapeutix up 13% at $14.22 on accelerated AXPAXLI NDA submission plans

2025-12-08T12:40:15.000Z - 6 months ago

Ocular Therapeutix up 13% at $14.22 on accelerated AXPAXLI NDA submission plans

Ocular announces plans to accelerate AXPAXLI NDA submission timeline

2025-12-08T12:11:15.000Z - 6 months ago

Ocular announces plans to accelerate AXPAXLI NDA submission timeline

Ocular Therapeutix price target raised to $21 from $19 at H.C. Wainwright

2025-12-08T11:15:06.000Z - 6 months ago

Ocular Therapeutix price target raised to $21 from $19 at H.C. Wainwright

Ocular Therapeutix reports inducement grant under Nasdaq listing rule

2025-12-05T12:05:31.000Z - 6 months ago

Ocular Therapeutix reports inducement grant under Nasdaq listing rule

Ocular Therapeutix Transcript: Piper Sandler 37th Annual Healthcare Conference

Dec 3, 2025, 8:30 AM EST - 6 months ago

Ocular Therapeutix Transcript: Piper Sandler 37th Annual Healthcare Conference

Ocular Therapeutix Transcript: Jefferies London Healthcare Conference 2025

Nov 18, 2025, 9:30 AM EST - 7 months ago

Ocular Therapeutix Transcript: Jefferies London Healthcare Conference 2025

Ocular Therapeutix Earnings Call Transcript: Q3 2025

Nov 4, 2025, 8:00 AM EST - 7 months ago

Ocular Therapeutix Earnings Call Transcript: Q3 2025

Ocular Therapeutix Quarterly report: Q3 2025

Nov 4, 2025, 8:00 AM EST - 7 months ago

Ocular Therapeutix Quarterly report: Q3 2025

Ocular Therapeutix Earnings release: Q3 2025

Nov 4, 2025, 8:00 AM EST - 7 months ago

Ocular Therapeutix Earnings release: Q3 2025

Ocular Therapeutix™ Reports Third Quarter 2025 Financial Results and Business Highlights

Nov 4, 2025, 7:05 AM EST - 7 months ago

Ocular Therapeutix™ Reports Third Quarter 2025 Financial Results and Business Highlights

Ocular Therapeutix™ Achieves Target Randomization of 555 Subjects in SOL-R

Nov 4, 2025, 7:00 AM EST - 7 months ago

Ocular Therapeutix™ Achieves Target Randomization of 555 Subjects in SOL-R

Ocular Therapeutix™ to Participate in Upcoming Scientific Conferences

Oct 7, 2025, 7:00 AM EDT - 8 months ago

Ocular Therapeutix™ to Participate in Upcoming Scientific Conferences

Ocular Therapeutix Transcript: Investor Day 2025

Sep 30, 2025, 2:00 PM EDT - 8 months ago

Ocular Therapeutix Transcript: Investor Day 2025

Ocular Therapeutix Press release: FY 2025

Sep 30, 2025, 2:00 PM EDT - 8 months ago

Ocular Therapeutix Press release: FY 2025

Ocular Therapeutix Slides: FY 2025

Sep 30, 2025, 2:00 PM EDT - 8 months ago

Ocular Therapeutix Slides: FY 2025

Ocular Therapeutix™ Announces Pricing of Underwritten Offering of Common Stock

Sep 30, 2025, 7:08 AM EDT - 8 months ago

Ocular Therapeutix™ Announces Pricing of Underwritten Offering of Common Stock

Ocular Therapeutix™ Investor Day to Highlight Exceptional AXPAXLI™ Progress Across SOL Program and Detail Registrational Trial Plans to Pursue a Diabetic Retinopathy Label with a Novel Primary Endpoint

Sep 30, 2025, 6:21 AM EDT - 8 months ago

Ocular Therapeutix™ Investor Day to Highlight Exceptional AXPAXLI™ Progress Across SOL Program and Detail Registrational Trial Plans to Pursue a Diabetic Retinopathy Label with a Novel Primary Endpoint

Ocular Therapeutix Transcript: Baird Global Healthcare Conference 2025

Sep 9, 2025, 12:50 PM EDT - 9 months ago

Ocular Therapeutix Transcript: Baird Global Healthcare Conference 2025

Ocular Therapeutix Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Sep 8, 2025, 2:35 PM EDT - 9 months ago

Ocular Therapeutix Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Ocular Therapeutix Transcript: H.C. Wainwright 5th Annual Ophthalmology Virtual Conference

Aug 13, 2025, 2:00 PM EDT - 10 months ago

Ocular Therapeutix Transcript: H.C. Wainwright 5th Annual Ophthalmology Virtual Conference

Ocular Therapeutix Earnings Call Transcript: Q2 2025

Aug 5, 2025, 8:00 AM EDT - 10 months ago

Ocular Therapeutix Earnings Call Transcript: Q2 2025

Ocular Therapeutix Quarterly report: Q2 2025

Aug 5, 2025, 8:00 AM EDT - 10 months ago

Ocular Therapeutix Quarterly report: Q2 2025

Ocular Therapeutix Earnings release: Q2 2025

Aug 5, 2025, 8:00 AM EDT - 10 months ago

Ocular Therapeutix Earnings release: Q2 2025

Ocular Therapeutix™ Unveils New Corporate Branding, Reflecting its Transformation to a Retina-Focused Company

Jun 26, 2025, 1:54 PM EDT - 1 year ago

Ocular Therapeutix™ Unveils New Corporate Branding, Reflecting its Transformation to a Retina-Focused Company

Ocular Therapeutix™ to Participate in Clinical Trials at the Summit (CTS) 2025

Jun 16, 2025, 7:00 AM EDT - 1 year ago

Ocular Therapeutix™ to Participate in Clinical Trials at the Summit (CTS) 2025

Ocular Therapeutix Transcript: Stifel 2025 Virtual Ophthalmology Forum

May 27, 2025, 3:00 PM EDT - 1 year ago

Ocular Therapeutix Transcript: Stifel 2025 Virtual Ophthalmology Forum

Ocular Therapeutix Transcript: H.C. Wainwright 3rd Annual BioConnect Investor Conference 2025

May 20, 2025, 4:30 PM EDT - 1 year ago

Ocular Therapeutix Transcript: H.C. Wainwright 3rd Annual BioConnect Investor Conference 2025

Ocular Therapeutix Transcript: RBC Capital Markets Global Healthcare Conference 2025

May 20, 2025, 2:35 PM EDT - 1 year ago

Ocular Therapeutix Transcript: RBC Capital Markets Global Healthcare Conference 2025

Ocular Therapeutix™ to Participate in Upcoming Investor Conferences

May 14, 2025, 7:00 AM EDT - 1 year ago

Ocular Therapeutix™ to Participate in Upcoming Investor Conferences

Ocular Therapeutix Transcript: Bank of America 2025 Healthcare Conference

May 13, 2025, 12:20 PM EDT - 1 year ago

Ocular Therapeutix Transcript: Bank of America 2025 Healthcare Conference

Ocular Therapeutix Transcript: The Citizens JMP Life Sciences Conference 2025

May 7, 2025, 9:00 AM EDT - 1 year ago

Ocular Therapeutix Transcript: The Citizens JMP Life Sciences Conference 2025

Ocular Therapeutix Quarterly report: Q1 2025

May 5, 2025, 7:00 AM EDT - 1 year ago

Ocular Therapeutix Quarterly report: Q1 2025

Ocular Therapeutix Earnings release: Q1 2025

May 5, 2025, 7:00 AM EDT - 1 year ago

Ocular Therapeutix Earnings release: Q1 2025

Ocular Therapeutix Proxy statement: Proxy Filing

Apr 29, 2025, 8:00 AM EDT - 1 year ago

Ocular Therapeutix Proxy statement: Proxy Filing

Ocular Therapeutix Proxy statement: Proxy Filing

Apr 29, 2025, 8:00 AM EDT - 1 year ago

Ocular Therapeutix Proxy statement: Proxy Filing

Ocular Therapeutix Proxy statement: Proxy Filing

Apr 18, 2025, 8:00 AM EDT - 1 year ago

Ocular Therapeutix Proxy statement: Proxy Filing

Ocular Therapeutix Transcript: 24th Annual Needham Virtual Healthcare Conference

Apr 7, 2025, 3:00 PM EDT - 1 year ago

Ocular Therapeutix Transcript: 24th Annual Needham Virtual Healthcare Conference

Ocular Therapeutix™ to Participate in Two Investor Conferences in April

Mar 31, 2025, 7:00 AM EDT - 1 year ago

Ocular Therapeutix™ to Participate in Two Investor Conferences in April

Ocular Therapeutix Slides: Corporate Presentation

Mar 27, 2025, 7:00 PM EDT - 1 year ago

Ocular Therapeutix Slides: Corporate Presentation

Ocular Therapeutix Transcript: Leerink Global Healthcare Conference 2025

Mar 10, 2025, 10:00 AM EDT - 1 year ago

Ocular Therapeutix Transcript: Leerink Global Healthcare Conference 2025

Ocular Therapeutix Transcript: TD Cowen 45th Annual Healthcare Conference

Mar 4, 2025, 11:50 AM EST - 1 year ago

Ocular Therapeutix Transcript: TD Cowen 45th Annual Healthcare Conference

Ocular Therapeutix Earnings Call Transcript: Q4 2024

Mar 3, 2025, 8:00 AM EST - 1 year ago

Ocular Therapeutix Earnings Call Transcript: Q4 2024

Ocular Therapeutix Annual report: Q4 2024

Mar 3, 2025, 8:00 AM EST - 1 year ago

Ocular Therapeutix Annual report: Q4 2024

Ocular Therapeutix Earnings release: Q4 2024

Mar 3, 2025, 8:00 AM EST - 1 year ago

Ocular Therapeutix Earnings release: Q4 2024

Ocular Therapeutix™ to Report Fourth Quarter and Full Year 2024 Results on March 3, 2025

Feb 24, 2025, 7:00 AM EST - 1 year ago

Ocular Therapeutix™ to Report Fourth Quarter and Full Year 2024 Results on March 3, 2025

Ocular Therapeutix™ Announces Upcoming Presentations at the Angiogenesis, Exudation, and Degeneration 2025 Virtual Meeting

Feb 3, 2025, 7:00 AM EST - 1 year ago

Ocular Therapeutix™ Announces Upcoming Presentations at the Angiogenesis, Exudation, and Degeneration 2025 Virtual Meeting

Ocular Therapeutix™ Shares SOL-R Enrollment Progress and Next Steps for AXPAXLI™ in NPDR

Jan 14, 2025, 7:00 AM EST - 1 year ago

Ocular Therapeutix™ Shares SOL-R Enrollment Progress and Next Steps for AXPAXLI™ in NPDR

Ocular Therapeutix Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Jan 13, 2025, 8:15 PM EST - 1 year ago

Ocular Therapeutix Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Ocular Therapeutix™ to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 10, 2024, 7:30 AM EST - 1 year ago

Ocular Therapeutix™ to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Ocular Therapeutix Transcript: Piper Sandler 36th Annual Healthcare Conference

Dec 3, 2024, 1:30 PM EST - 1 year ago

Ocular Therapeutix Transcript: Piper Sandler 36th Annual Healthcare Conference

Ocular Therapeutix™ Announces More Than 300 Subjects Randomized in SOL-1

Dec 2, 2024, 7:30 AM EST - 1 year ago

Ocular Therapeutix™ Announces More Than 300 Subjects Randomized in SOL-1

Ocular Therapeutix™ to Participate in December Investor and Scientific Conferences

Nov 26, 2024, 7:30 AM EST - 1 year ago

Ocular Therapeutix™ to Participate in December Investor and Scientific Conferences

Ocular Therapeutix Earnings Call Transcript: Q3 2024

Nov 14, 2024, 8:00 AM EST - 1 year ago

Ocular Therapeutix Earnings Call Transcript: Q3 2024

Ocular Therapeutix Quarterly report: Q3 2024

Nov 14, 2024, 8:00 AM EST - 1 year ago

Ocular Therapeutix Quarterly report: Q3 2024

Ocular Therapeutix Earnings release: Q3 2024

Nov 14, 2024, 8:00 AM EST - 1 year ago

Ocular Therapeutix Earnings release: Q3 2024

Ocular Therapeutix™ to Present at the Jefferies London Healthcare Conference and Ophthalmology Innovation Summit XIV

Nov 13, 2024, 7:30 AM EST - 1 year ago

Ocular Therapeutix™ to Present at the Jefferies London Healthcare Conference and Ophthalmology Innovation Summit XIV

Ocular Therapeutix™ to Report Third Quarter 2024 Results on November 14, 2024

Nov 6, 2024, 7:30 AM EST - 1 year ago

Ocular Therapeutix™ to Report Third Quarter 2024 Results on November 14, 2024

Ocular Therapeutix™ Announces Accelerated Timelines for SOL-1 Registrational Trial of AXPAXLI™ in Wet AMD

Oct 15, 2024, 7:30 AM EDT - 1 year ago

Ocular Therapeutix™ Announces Accelerated Timelines for SOL-1 Registrational Trial of AXPAXLI™ in Wet AMD

Ocular Therapeutix™ to Present at October Ophthalmology Meetings

Oct 9, 2024, 7:30 AM EDT - 1 year ago

Ocular Therapeutix™ to Present at October Ophthalmology Meetings

Ocular Therapeutix Transcript: UBS Virtual Ophthalmology Day

Oct 2, 2024, 3:00 PM EDT - 1 year ago

Ocular Therapeutix Transcript: UBS Virtual Ophthalmology Day

Ocular Therapeutix™ to Present at the UBS Virtual Opthalmology Day 2024

Sep 25, 2024, 7:30 AM EDT - 1 year ago

Ocular Therapeutix™ to Present at the UBS Virtual Opthalmology Day 2024

Ocular Therapeutix Transcript: H.C. Wainwright 26th Annual Global Investment Conference 2024

Sep 11, 2024, 8:30 AM EDT - 1 year ago

Ocular Therapeutix Transcript: H.C. Wainwright 26th Annual Global Investment Conference 2024

Ocular Therapeutix™ to Present at September Retina Meetings

Sep 5, 2024, 7:30 AM EDT - 1 year ago

Ocular Therapeutix™ to Present at September Retina Meetings

Ocular Therapeutix™ to Present at Two Investor Conferences in September

Sep 4, 2024, 7:30 AM EDT - 1 year ago

Ocular Therapeutix™ to Present at Two Investor Conferences in September

Ocular Therapeutix Earnings Call Transcript: Q2 2024

Aug 7, 2024, 8:00 AM EDT - 1 year ago

Ocular Therapeutix Earnings Call Transcript: Q2 2024

Ocular Therapeutix Quarterly report: Q2 2024

Aug 7, 2024, 8:00 AM EDT - 1 year ago

Ocular Therapeutix Quarterly report: Q2 2024

Ocular Therapeutix Earnings release: Q2 2024

Aug 7, 2024, 8:00 AM EDT - 1 year ago

Ocular Therapeutix Earnings release: Q2 2024

Ocular Therapeutix™ Reports Second Quarter 2024 Results

Aug 7, 2024, 7:10 AM EDT - 1 year ago

Ocular Therapeutix™ Reports Second Quarter 2024 Results

Ocular Therapeutix™ to Report Second Quarter 2024 Financial Results on August 7, 2024

Jul 31, 2024, 7:30 AM EDT - 2 years ago

Ocular Therapeutix™ to Report Second Quarter 2024 Financial Results on August 7, 2024

Ocular Therapeutix™ Announces First Patients Enrolled in Phase 3 SOL-R Wet AMD Study

Jul 30, 2024, 7:30 AM EDT - 2 years ago

Ocular Therapeutix™ Announces First Patients Enrolled in Phase 3 SOL-R Wet AMD Study

Ocular Therapeutix™ Announces Late-Breaking Abstract of HELIOS Study to be Presented at 42nd ASRS Annual Scientific Meeting

Jul 10, 2024, 8:00 AM EDT - 2 years ago

Ocular Therapeutix™ Announces Late-Breaking Abstract of HELIOS Study to be Presented at 42nd ASRS Annual Scientific Meeting

Ocular Therapeutix™ Highlights Exceptional AXPAXLI™ SOL-1 Enrollment and Plans for Repeat Dosing Study (SOL-R) in wet AMD at Investor Day, Along with Positive 48-week Data from HELIOS NPDR Study

Jun 13, 2024, 4:05 PM EDT - 2 years ago

Ocular Therapeutix™ Highlights Exceptional AXPAXLI™ SOL-1 Enrollment and Plans for Repeat Dosing Study (SOL-R) in wet AMD at Investor Day, Along with Positive 48-week Data from HELIOS NPDR Study

Ocular Therapeutix Transcript: Investor Day 2024

Jun 13, 2024, 2:00 PM EDT - 2 years ago

Ocular Therapeutix Transcript: Investor Day 2024

Ocular Therapeutix Slides: FY 2024

Jun 13, 2024, 2:00 PM EDT - 2 years ago

Ocular Therapeutix Slides: FY 2024

Ocular Therapeutix® to Host Investor Day on June 13, 2024

Jun 5, 2024, 7:30 AM EDT - 2 years ago

Ocular Therapeutix® to Host Investor Day on June 13, 2024

Ocular Therapeutix® Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jun 4, 2024, 4:05 PM EDT - 2 years ago

Ocular Therapeutix® Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Ocular Therapeutix Transcript: BofA Securities 2024 Health Care Conference

May 15, 2024, 6:00 PM EDT - 2 years ago

Ocular Therapeutix Transcript: BofA Securities 2024 Health Care Conference

Ocular Therapeutix Transcript: The Citizens JMP Life Sciences Conference

May 13, 2024, 1:00 PM EDT - 2 years ago

Ocular Therapeutix Transcript: The Citizens JMP Life Sciences Conference

Ocular Therapeutix™ Reports First Quarter 2024 Results

May 7, 2024, 4:05 PM EDT - 2 years ago

Ocular Therapeutix™ Reports First Quarter 2024 Results

Ocular Therapeutix Quarterly report: Q1 2024

May 7, 2024, 4:00 PM EDT - 2 years ago

Ocular Therapeutix Quarterly report: Q1 2024

Ocular Therapeutix Earnings release: Q1 2024

May 7, 2024, 4:00 PM EDT - 2 years ago

Ocular Therapeutix Earnings release: Q1 2024

Ocular Therapeutix Proxy statement: Proxy Filing

May 7, 2024, 8:00 AM EDT - 2 years ago

Ocular Therapeutix Proxy statement: Proxy Filing

Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 6, 2024, 8:16 PM EDT - 2 years ago

Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Ocular Therapeutix™ to Present at Two Upcoming Investor Conferences

May 6, 2024, 7:30 AM EDT - 2 years ago

Ocular Therapeutix™ to Present at Two Upcoming Investor Conferences

Ocular Therapeutix™ To Present at Two Ophthalmology Meetings, May 4-9, 2024

May 3, 2024, 7:30 AM EDT - 2 years ago

Ocular Therapeutix™ To Present at Two Ophthalmology Meetings, May 4-9, 2024

Ocular Therapeutix™ to Host Investor Day in New York City on Thursday, June 13, 2024

May 1, 2024, 7:30 AM EDT - 2 years ago

Ocular Therapeutix™ to Host Investor Day in New York City on Thursday, June 13, 2024

Ocular Therapeutix Proxy statement: Proxy Filing

Apr 29, 2024, 8:00 AM EDT - 2 years ago

Ocular Therapeutix Proxy statement: Proxy Filing

Ocular Therapeutix Proxy statement: Proxy Filing

Apr 19, 2024, 8:00 AM EDT - 2 years ago

Ocular Therapeutix Proxy statement: Proxy Filing

Ocular Therapeutix™ Announces Positive Topline Phase 1 Data for AXPAXLI™ in Diabetic Retinopathy

Apr 18, 2024, 7:00 AM EDT - 2 years ago

Ocular Therapeutix™ Announces Positive Topline Phase 1 Data for AXPAXLI™ in Diabetic Retinopathy

Ocular Therapeutix™ Executive Chairman Pravin U. Dugel, MD Becomes President and CEO Antony Mattessich is Stepping Down as President and CEO

Apr 15, 2024, 7:00 AM EDT - 2 years ago

Ocular Therapeutix™ Executive Chairman Pravin U. Dugel, MD Becomes President and CEO Antony Mattessich is Stepping Down as President and CEO

Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Senior Vice President of Global Head of Biometrics

Apr 9, 2024, 7:30 AM EDT - 2 years ago

Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Senior Vice President of Global Head of Biometrics

onlyGreenPlz
onlyGreenPlz Jun. 4 at 11:57 PM
$OCUL I heard he left in the blink of an eye.
1 · Reply
MaxKlim
MaxKlim Jun. 4 at 11:18 PM
$OCUL The former head of ophthalmology of the FDA will discuss safety and the future !!! His receivers will make a decision, as he retired and left his pupils!
0 · Reply
QuietTrader
QuietTrader Jun. 4 at 3:34 PM
$OCUL Where are those people doubting this move. In at 8.24 a few days ago, out at 8.90 today with a very nice gain. I hope this goes to the moon to screw all the nasty shorts. I really do. Good luck folks… until we meet again!
0 · Reply
Unicorn2020
Unicorn2020 Jun. 4 at 1:51 PM
$OCUL Don't ever forget French pharmaceutical giant Sanofi made a discreet, formal proposal to acquire Ocular Therapeutix for $16 per share = $2.3 billion valuation. And got rejected!
3 · Reply
Fairvalue10
Fairvalue10 Jun. 4 at 1:50 PM
$OCUL It would be very logical that, as we get closer to June 17, we see a bullish momentum and break above 10. It's quite inconceivable that there are 22 million shorts approaching an event that could be a real catalyst. Tomorrow and next week should be favorable to all longs.
2 · Reply
MaxKlim
MaxKlim Jun. 4 at 1:39 PM
$OCUL back to 9,3$ this week !!!! Go go go
0 · Reply
MaxKlim
MaxKlim Jun. 4 at 12:58 PM
$OCUL
0 · Reply
Fairvalue10
Fairvalue10 Jun. 4 at 12:41 PM
$OCUL Busy, Busy : BEDFORD, Mass., June 04, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced participation at Clinical Trials at the Summit 2026, taking place on June 12-13, 2026, in Las Vegas, Nevada.
0 · Reply
Nikkosi
Nikkosi Jun. 4 at 11:44 AM
$OCUL “Bringing Novel Treatments to Market” on Saturday, June 13th. Alarm is set. I’ll definitely be tuning in and listening attentively—should be an interesting discussion with plenty of valuable insights.
1 · Reply
BuyoutBobby
BuyoutBobby Jun. 4 at 11:12 AM
$OCUL the pipeline of Re-Vana is probably interesting for ophthalmology interested people especially because they are working on sustained release drugs with some big pharma companies.
0 · Reply
WarrenDouglasTrader
WarrenDouglasTrader Jun. 4 at 3:39 AM
$OCUL Technicals are very poor---below 8 and 21 dema. Need that NDA! Wtf
0 · Reply
Unicorn2020
Unicorn2020 Jun. 3 at 8:18 PM
$OCUL Bought 3K shares yesterday @ $8.15. Added 7K shares with the same price $8.15 today. The GEM at this price.
0 · Reply
MaxKlim
MaxKlim Jun. 3 at 7:41 PM
$OCUL When will shopping for the event start on June 17? Next week?
1 · Reply
BigTrucks
BigTrucks Jun. 3 at 6:01 PM
$ALDX $OCUL Added a few here, but money is on FDA for $OTLK It's sitting at .80 for now. If you have heard the won FDR appeal.. Which is a rarity!!!
0 · Reply
Tmoney85285
Tmoney85285 Jun. 3 at 4:09 PM
$OCUL another borderline embarrassing day from the pump show! my guess is investor day is going to be the biotech equivalent of fyre fest...cheese sandwiches and broken promises!
0 · Reply
QuietTrader
QuietTrader Jun. 3 at 1:43 PM
Stocks to watch: $META News from London pending and it might be huge. Expecting a big move. $OCUL Something brewing here too (see my chart from yesterday) $NVTS flying this morning $XBI Recovering from yesterday
1 · Reply
MaxKlim
MaxKlim Jun. 3 at 1:26 PM
$OCUL
0 · Reply
TickrTalk0007
TickrTalk0007 Jun. 3 at 12:46 PM
$OCUL institutions selling 50% and holding rest for NDA submission pump....The FDA WILL ask for SOL-R data before approving....Pravin thinks he is smarter than rest and will pump on "NDA submission with 1 trial" but then end up submitting SOL-R to support NDA...misleading and should be put in jail
0 · Reply
Lixothetinman
Lixothetinman Jun. 3 at 7:42 AM
$OCUL these are the drops you take advantage of. Have some LT, but also bought yesterday for a swing.
1 · Reply
BuyoutBobby
BuyoutBobby Jun. 3 at 6:50 AM
$OCUL sounds like they will announce on that investor day that the FDA said they need SOL-R for the NDA.
2 · Reply
abubnic
abubnic Jun. 2 at 10:16 PM
$OCUL Investors Day in two weeks. Expect updates.
0 · Reply
QuietTrader
QuietTrader Jun. 2 at 6:50 PM
$OCUL Intraday showing good MoneyFlow, high MarketForecast and improving Market Sentiment. Momentum flat at the moment. And those upward facing purple arrows are signaling strong buy signals. She’s going higher.
0 · Reply